Satellos Bioscience Inc
XTSX:MSCL
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
N/A
N/A
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CAD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Satellos Bioscience Inc
EPS (Diluted)
Satellos Bioscience Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Satellos Bioscience Inc
XTSX:MSCL
|
EPS (Diluted)
CA$0
|
CAGR 3-Years
0%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
Theratechnologies Inc
TSX:TH
|
EPS (Diluted)
$0
|
CAGR 3-Years
29%
|
CAGR 5-Years
5%
|
CAGR 10-Years
-5%
|
|
|
Repare Therapeutics Inc
NASDAQ:RPTX
|
EPS (Diluted)
-$1
|
CAGR 3-Years
-43%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
EPS (Diluted)
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
EPS (Diluted)
-$3
|
CAGR 3-Years
-31%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
-38%
|
|
|
Spectral Medical Inc
TSX:EDT
|
EPS (Diluted)
CA$0
|
CAGR 3-Years
-55%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
-14%
|
|
Satellos Bioscience Inc
Glance View
Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. The company is headquartered in Toronto, Ontario. The company went IPO on 2006-12-01. The firm is engaged in developing therapeutics that stimulate or restore muscle regeneration in severe disorders. Its lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct dysregulated muscle stem-cell polarity, which balances replenishment of muscle stem cells and production of specialized tissue cells. The company uses MyoReGenXTM discovery platform to identify regulatory pathways and drug candidates to treat muscle disorders. The company also maintains two clinical stage products: iCo-008 for potential use in eotaxin-1 mediated indications and an oral Amphotericin B delivery system. iCo-008 provides treatment of the dermatological condition bullous pemphigoid (BP), atopic dermatitis, gastrointestinal conditions, and age-related macular degeneration (AMD). Oral Amphotericin B delivery system provides treatment of Visceral Leishmaniasis (VL).
See Also
What is Satellos Bioscience Inc's EPS (Diluted)?
EPS (Diluted)
-0.3
CAD
Based on the financial report for Dec 31, 2022, Satellos Bioscience Inc's EPS (Diluted) amounts to -0.3 CAD.
What is Satellos Bioscience Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
-2%
Over the last year, the EPS (Diluted) growth was 50%.